“Click” amphotericin B in prodrug nanoformulations for enhanced systemic fungemia treatment
Authors:
- 15 May 2024
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 370, 626-642
Abstract
No abstract availableKeywords
Funding Information
- National Institute of General Medical Sciences (1R01GM130941-01)
- National Institute of General Medical Sciences (1R35GM149321)
- National Institute of General Medical Sciences (PR221368)
- National Institutes of Health
- Foundation for Ichthyosis and Related Skin Types
This publication has 69 references indexed in Scilit:
- Amphotericin B release rate is the link between drug status in the liposomal bilayer and toxicityAsian Journal of Pharmaceutical Sciences, 2022
- Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal InfectionsInfectious Diseases and Therapy, 2021
- Mechanism of Candida pathogenesis: revisiting the vital driversEuropean Journal of Clinical Microbiology & Infectious Diseases, 2020
- Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticalsAdvanced Drug Delivery Reviews, 2020
- Biodegradable functional polycarbonate micelles for controlled release of amphotericin BActa Biomaterialia, 2016
- ROS‐responsive drug delivery systemsBioengineering & Translational Medicine, 2016
- Fast and Tight Boronate Formation for Click Bioorthogonal ConjugationAngewandte Chemie, 2016
- Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future DirectionsDrugs, 2016
- Biodegradable Nanoparticles Improve Oral Bioavailability of Amphotericin B and Show Reduced Nephrotoxicity Compared to Intravenous Fungizone®Pharmaceutical Research, 2009
- Evaluation of Five Commercial Sabouraud Gentamicin-Chloramphenicol Agar MediaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2001